Form 4: Opus Genetics Director Receives Stock Grant

Director Cam Gallagher was granted 24,367 restricted stock units in Opus Genetics, Inc. as part of a standard equity compensation arrangement.

Summary

• Director Cam Gallagher acquired 24,367 restricted stock units (RSUs) of Opus Genetics, Inc. common stock.
• The transaction occurred on April 20, 2026, at a price of $0 per share, representing an equity grant.
• Following this transaction, the reporting person directly owns 2,015,797 shares of common stock.
• The reporting person also maintains indirect ownership of 83,000 shares held as custodian for a minor child.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing regarding routine director compensation.

Positives

• The grant aligns the director's interests with those of shareholders through equity-based compensation.
• The director maintains a significant direct ownership stake of over 2 million shares.

Negatives

• None identified; this is a standard compensatory equity grant.

Risks

• Vesting of the RSUs is subject to the reporting person's continuing service through the vesting date.

Future Outlook

The RSUs vest on the earlier of the one-year anniversary of the grant date or the day prior to the Issuer's next annual meeting of stockholders, contingent upon continued service.

Management Comments

• The grant is subject to the Reporting Person's continuing service through the vesting date.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment between board members and company performance.

Comparison to Industry Standards

• The use of RSU grants for board compensation is consistent with standard practices for small-cap biotechnology firms.
• The vesting schedule of one year or the next annual meeting is a typical retention mechanism for board members.

Related Party Transactions

• The reporting person holds 83,000 shares as custodian for a minor child under the Uniform Transfer to Minors Act.

Stakeholder Impact

• Minimal impact on shareholders as this is a standard equity compensation event.

Next Steps

• Vesting of the 24,367 RSUs on the earlier of April 20, 2027, or the day prior to the next annual meeting.

Key Dates

Keywords

Opus Genetics, IRD, Form 4, Insider Trading, Director Compensation, Restricted Stock Units